These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21545241)

  • 1. Adverse reactions to duloxetine in depression.
    Bitter I; Filipovits D; Czobor P
    Expert Opin Drug Saf; 2011 Nov; 10(6):839-50. PubMed ID: 21545241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ; Ogilvie AD; Gama J
    Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
    Mease PJ; Russell IJ; Kajdasz DK; Wiltse CG; Detke MJ; Wohlreich MM; Walker DJ; Chappell AS
    Semin Arthritis Rheum; 2010 Jun; 39(6):454-64. PubMed ID: 19152958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
    Wu WY; Wang G; Ball SG; Desaiah D; Ang QQ
    Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of duloxetine during pregnancy and lactation.
    Andrade C
    J Clin Psychiatry; 2014 Dec; 75(12):e1423-7. PubMed ID: 25551238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.
    Choy EH; Mease PJ; Kajdasz DK; Wohlreich MM; Crits-Christoph P; Walker DJ; Chappell AS
    Clin Rheumatol; 2009 Sep; 28(9):1035-44. PubMed ID: 19533210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS; Loft H; Dragheim M
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.